Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study

Harb, Ola A.; Kaf, Randa Mohamed; Taha, Heba F.; Ahmed, Rham Z.; Mandour, Doaa; Al Attar, Ahmed Z.; Fathy, Ayman; Almoregy, Abdelwahab S.; Osman, Gamal; Gertallah, Loay M.

doi:10.1186/s42047-019-0038-7

Table 3 Correlation between PD-L1, FOXP-1 and STAT-3 expression and outcome of our patients

From: Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study

Characteristics	All	PD-L1		p-value	FOXP-1		p-value	STAT-3		p-value
	All	Low (N = 31)	High (N = 19)		Low (N = 29)	High (N = 21)		Low (N = 27)	High (N = 23)
	(N = 50)	Low (N = 31)	High (N = 19)		Low (N = 29)	High (N = 21)		Low (N = 27)	High (N = 23)
	No. (%)	No. (%)	No. (%)		No. (%)	No. (%)		No. (%)	No. (%)
Response
PD	3 (6%)	1 (3.2%)	2 (10.5%)	0.013^a	1 (3.4%)	2 (9.5%)	0.030^a	0 (0%)	3 (13%)	0.044^a
SD	2 (10.5%)	0 (0%)	2 (10.5%)		0 (0%)	2 (9.5%)		1 (3.7%)	1 (4.3%)
PR	3 (6%)	0 (0%)	3 (15.8%)		0 (0%)	3 (14.3%)		0 (0%)	3 (13%)
CR	42 (84%)	30 (96.8%)	12 (63.2%)		]28 (96.6%)	14 (66.7%)		26 (96.3%)	16 (69.6%)
NR	5 (10%)	1 (3.2%)	4 (21.1%)	0.062^a	1 (3.4%)	4 (19%)	0.148^a	1 (3.7%)	4 (17.4%)	0.467^a
OAR	45 (90%)	30 (96.8%)	15 (78.9%)		28 (96.6%)	17 (81%)		26 (96.3%)	19 (82.6%)
Relapse	(N = 42)	(N = 30)	(N = 12)		(N = 28)	(N = 14)		(N = 26)	(N = 16)
Absent	28 (66.7%)	26 (86.7%)	2 (16.7%)	< 0.001^a	27 (96.4%)	1 (7.1%)	< 0.001^a	22 (84.6%)	6 (37.5%)	0.002^a
Present	14 (33.3%)	4 (13.3%)	10 (83.3%)	< 0.001^a	1 (3.6%)	13 (92.9%)	< 0.001^a	4 (15.4%)	10 (62.5%)	0.002^a
RFS
Mean (months)	30.11	33.72	20.35	< 0.001^b	35.81	18.42	< 0.001^b	35.81	18.42	< 0.001^b
(95%CI)	(27.27–32.95)	(31.42–36.03)	(15.42–25.27)		(35.45–36.17)	(14.32–22.52)		(35.45–36.17)	(14.32–22.52)
1 year RFS	90.5%	96.7%	75%		100%	71.4%		96.2%	81.3%
2 year RFS	73.6%	90%	30%		100%	21.4%		88.5%	48.6%
3 year RFS	66.1%	86.5%	10%		96.3%	7.1%		84.4%	34.7%
Mortality	(N = 50)	(N = 31)	(N = 19)		(N = 29)	(N = 21)		(N = 27)	(N = 23)
Alive	33 (66%)	29 (93.5%)	4 (21.1%)	< 0.001^a	29 (100%)	4 (19%)	< 0.001^a	24 (88.9%)	9 (39.1%)	< 0.001^a
Died	17 (34%)	2 (6.5%)	15 (78.9%)	< 0.001^a	0 (0%)	17 (81%)	< 0.001^a	3 (11.1%)	14 (60.9%)	< 0.001^a
OS
Mean (months)	29.78	34.77	21.18	< 0.001^b	36	21.09	< 0.001^b	33.92	24.80	< 0.001^b
(95%CI)	(27.23–32.34)	(33.12–36.42)	(17.37–24.99)			(17.51–24.68)		(31.70–36.14)	(20.72–28.89)
1 year OS	92%	100%	78.9%		100%	81%		100%	82.6%
2 year OS	69.8%	93.5%	29.6%		100%	28.6%		88.9%	46.8%
3 year OS	65.7%	93.5%	17.8%		100%	19%		88.9%	37.5%

Continuous variables were expressed as mean (95%CI); categorical variables were expressed as number (percentage); ^a Chi-square test; ^b Log rank test; p < 0.05 is significant

Back to article page

ISSN: 2520-8454

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@springeropen.com

Surgical and Experimental Pathology

Contact us